Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,09:00-12:05
Biosimilars Commercialization & Global Launch Session(China Focus)
Stay tuned
Special Session Planning
Ke Shao:Deputy General Manager, Kexing Biopharm
Jiali Luo:CEO, TOBIO Group
09:00-09:05 Host Opening
Ke Shao:Deputy General Manager, Kexing Biopharm
09:05-09:25 Investment in China's Biomedical Industry and Future Industrial Trends
Xun Zhu :Founding Chairman, Tonacea New Drug Talent Club
09:25-09:45 Opportunities and Strategic Choices for Chinese Enterprises Under the New Global Landscape of Biosimilars
Han Bai:Principal, Custom Solutions,APAC Norstella
09:45-10:05 CMC Development and Commercialization of Biosimilars
Jun Ma:Principal, Custom Solutions,APAC Norstella
10:05-10:25 From Followers to Pioneers: Reshaping the Global Biosimilars Landscape
Max Fernandez:VP, Intellective Biologics (Suzhou) Co., Ltd.
10:25-10:45 Opportunities and Challenges of Global Biosimilars: Exploration and Reflections of Kexing Biopharm
Ke Shao:Deputy General Manager, Kexing Biopharm
10:45-11:25 Joint Efforts for Mass Production: Large-Scale Manufacturing and Cost Optimization of Biosimilars
Moderator: Jiali Luo, Ascendis Biologics:CEO of Asymchem Biologics Group
Sheng Zhou: Deputy General Manager of Lisure Technology
More guests are being invited .....
11:25-12:05 Biosimilars Overseas Expansion Roundtable
Ke Shao(host):Deputy General Manager, Kexing Biopharm
More guests are being invited .....